Marie Anne Gebara

Correction to: Neuropsychopharmacology https://doi.org/10.1038/s41386-026-02338-w, published online 19 February 2026 Figure 3’s legend is updated. The legend said “b The “Benign vs. pernicious depression” approach proposes that…; whereas the figure itself shows “Simple vs. complex depression” (and elsewhere in the paper we use that terminology). Therefore, the legend should say “b The “Simple vs. complex depression” approach proposes that...

Abstract The pharmacotherapy of late-life depression (LLD) is characterized by clinical complexity. Older adults are living longer with multimorbidity, frailty and polypharmacy, and are taking more CNS-active medications and substances. These add to the risk and complexity of adding or changing depression treatment. At the same time, there are more medication options for depression and the use of many of them entails balancing potentials risks and benefits.

This is an analysis of secondary outcomes in an open-label late-life TRD study examining the safety, tolerability, and feasibility of IV ketamine infusions. In the acute phase, participants ( N = 25) aged 60 years or older received twice-a-week IV ketamine for 4 weeks. Then, participants with Montgomery-Asberg Depression Rating Scale (MADRS) total score <10 or ≥ 30% reduction from baseline proceeded to the continuation phase, an additional four weeks of once-a-week IV ketamine.